PacificHealth Laboratories, Inc.

PacificHealth Laboratories, Inc.

PHLI
PacificHealth Laboratories, Inc.US flagOther OTC
0.00
USD
+0.00
- -
438,307.00Market Cap
PacificHealth Laboratories, Inc.
PHLI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
TTM
FRC
1.55
0.98
0.22
0.46
0.84
1.12
0.84
0.77
0.67
0.53
0.52
0.56
0.53
0.53
0.45
0.35
0.32
Revenue per Share
0.05
-1.24
-0.55
-0.26
-0.21
0.05
-0.42
-0.2
-0.25
-0.06
0.19
-0.1
-0.15
-0.11
-0.05
-0.02
-0.05
Basic EPS, GAAP
-1.3
-0.6
-0.53
-0.35
-0.39
-0.09
-0.23
-0.15
-0.16
-0.11
-0.15
-0.12
-0.05
-0.06
-0.02
-0.03
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.1
-1.35
-1.56
-1.82
-2.02
-1.65
-1.9
-1.83
-1.52
-1.58
-1.17
-1.14
-1.26
-1.26
-1.21
-1.03
-0.98
Book Value per Share
1.75
1.79
0.81
0.55
0.39
0.86
0.37
0.39
0.02
-0.04
0.33
0.28
0.18
0.08
0.03
0.06
0.04
Tangible Book Value per Share
2
3
5
5
5
5
6
7
10
10
12
13
14
15
16
20
21
Basic Weighted Avg Shares
3
3
1
2
4
6
5
5
7
5
6
7
7
8
7
7
7
Sales/Revenue/Turnover
3.23
-126.47
-270
-85.71
-34.55
5.53
-50.44
-25.71
-35.61
-37.47
-6.88
-18.32
-21.67
-23.26
-10.56
-6.86
-13.9
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-4
-2
-1
-1
- -
-3
-1
-3
-1
2
-1
-2
-2
-1
- -
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
36.03
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
3.23
-126.47
-250
-57.14
-24.93
4.65
-50.2
-26.61
-37.04
-11.65
36.54
-17.18
-27.56
-20.96
-10.57
-7.03
-14.15
Profit Margin (%)
3
6
4
2
2
5
2
3
- -
1
4
3
2
1
- -
1
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
4
6
4
2
2
5
2
3
- -
1
4
4
2
1
1
1
1
Total Equity
- -
- -
- -
- -
- -
10.39
- -
- -
- -
- -
-10.5
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-3.14
- -
- -
- -
- -
-15.95
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'12
Jun'12
Sep'12
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
4
4
3

Working Capital

FRC

in mil. unless spec.
Mar'12
Jun'12
Sep'12
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.86%
-4.79%
121.46%
Free Cash Flow
21.46%
-3.6%
103.45%
Net Income, GAAP
-170.91%
-41.32%
-36.13%
Sales/Revenue/Turnover
2.23%
2.72%
-3.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
2
3
2
1
7
2011
2
2
2
1
7
2012
2
2
2
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
-0.02
0.01
-0.01
- -
-0.05
2011
- -
- -
-0.01
- -
-0.02
2012
- -
- -
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
Business
PacificHealth Laboratories, Inc. develops and markets protein-based nutritional products primarily targeting sports performance, hydration, fueling, and muscle recovery. Its core product portfolio includes powdered and ready-to-drink supplements such as ENDUROX R4, a muscle recovery drink with a patented 4:1 carbohydrate-protein ratio; ACCELERADE, a protein-powered sports drink; ACCEL GEL and 2ND SURGE energy gels designed to enhance endurance and reduce muscle fatigue; ENDUROX EXCEL, a supplement containing adaptogens for immune support and improved exercise performance; and ACCELERADE HYDRO, formulated for hydration and energy during less intense workouts. The company also offers Immuno ARMOR and other immune-support products under its nutrition brand. Founded in 1995 and headquartered in Matawan, New Jersey, PacificHealth Laboratories collaborates extensively with nutritionists, biochemists, and sports scientists to develop its proprietary formulations. Notably, the company has pioneered research on the critical muscle recovery window post-exercise and the efficacy of combining carbohydrates and proteins for muscle performance enhancement. Recent strategic advancements include leadership changes with Jason Ash promoted to CEO, ongoing product innovation in sports nutrition and immunity, and efforts to expand market reach through specialized retailers and digital channels. The company operates primarily in the United States but serves international markets with a focus on endurance athletes, triathletes, and fitness enthusiasts. PacificHealth Laboratories continues to emphasize scientific research-driven product development and has recently enhanced its product offerings in endurance, recovery, hydration, and immune support categories. Its products are distributed through sports specialty stores, natural product retailers, and direct online sales, reflecting a comprehensive approach to the sports nutrition segment. The company's innovations remain rooted in evidence-based nutrition principles, maintaining a strong position in the competitive sports supplement industry.